Speakers - CRDWC 2025

Amrendra K Ajay

  • Designation: Harvard Medical School
  • Country: USA
  • Title: BRCA1 Deletion Protects Mice from Kidney Fibrosis by Reducing G2M Cell Cycle Arrest

Abstract

Chordomas account for approximately 1-4% of all malignant bone tumors and around 20% of primary tumors of the spinal column. It is a rare disease, with an incidence estimated to be approximately 1 per 1,000,000 people. The underlying mechanism of chordoma is unknown, which makes it challenging for treatment. Chordomas have been linked to the T gene located on chromosome 6. T gene encodes a protein transcription factor T or brachyury homolog. Currently, there is no approved therapy for chordoma. Here, we performed small molecule screening to identify molecular and chemical therapeutic targets for chordoma. We found proteasome as a molecular target and proteasomal inhibitors to significantly reduce the proliferation of human chordoma cells. Further, we discovered that proteasomal subunits PSMB5 and PSMB8 are increased in human chordoma cell lines U-CHD1 and U-CHD2. Thus, proteasome inhibition may serve as a therapeutic target for the treatment of chordoma.

Don't miss our future updates!

Get in Touch